Obesity Medication Significantly Reduces Risk of Infections and Serious Cardiovascular Events
Key Takeaways:
- Tirzepatide cut the combined risk of heart attack, stroke and death by around a third compared with sitagliptin over one year.
- Hospital admissions for infection fell by 36 per cent, and infection-related deaths by 60 per cent.
- Real-world insurance data offers evidence on GLP-1 medications that clinical trials have not yet produced.
A large real-world comparison of two diabetes medicines
People living with type 2 diabetes and obesity may gain substantially more than improved blood glucose control from treatment with tirzepatide. New research indicates that the medication, marketed as Mounjaro, is associated with roughly a one-third reduction in the risk of heart attack and a similar reduction in hospital admissions for infection, when compared with a conventional diabetes medication.
The findings come from researchers at the Technical University of Munich (TUM) and Harvard Medical School, who used health insurance data to examine how the drug performs outside the tightly controlled conditions of a clinical trial. Their study has been published in The BMJ.
What the researchers did
The team analysed a large dataset drawn from United States health insurance providers, comparing outcomes among people treated with tirzepatide against those treated with sitagliptin. Sitagliptin was chosen deliberately: it is a diabetes medication regarded as neutral with respect to cardiovascular outcomes, which makes it a useful yardstick for isolating any additional benefit attributable to tirzepatide.
That design matters. Rather than measuring tirzepatide against a placebo, the researchers set it against an established, widely used treatment that people with type 2 diabetes might realistically be prescribed instead – a comparison closer to the decisions clinicians and patients actually face.
Cardiovascular events reduced by around a third
The results pointed to clear advantages for the GLP-1 medication, a class that has drawn considerable public attention in recent years for its effects on weight.
After one year, 4.4 per cent of people treated with the comparator drug had experienced a heart attack or a stroke, or had died. Among those treated with tirzepatide, the figure was 2.9 per cent. The gap corresponds to a relative risk reduction of approximately one third.
Expressed in absolute terms, the difference of roughly 1.5 percentage points over a single year is meaningful in a population already carrying elevated cardiovascular risk from both type 2 diabetes and obesity.
Fewer hospital admissions for infection
The second set of findings was less anticipated. Significantly fewer people treated with tirzepatide were admitted to hospital with infections, with the associated risk reduced by 36 per cent. The risk of dying from an infection was reduced by as much as 60 per cent.
“The data on infections surprised us because the findings were so striking,” says Dr. Nils Krüger, first author of the study and a resident physician in the Department of Cardiovascular Diseases at TUM University Hospital. “Previous studies have suggested that people treated with GLP-1 agonists are less likely to be hospitalized for infections and less likely to die from them.”
In other words, the direction of the signal was not new – but its size was.
Why obesity may affect the immune response
According to Dr Krüger, the reasons behind the association are not yet fully understood. One plausible explanation lies in the relationship between excess adiposity and chronic inflammation.
“There is evidence that obesity promotes inflammatory processes in the body, which may in turn impair immune function. The exact mechanisms and whether this apparent benefit would also occur without weight loss now need to be investigated.”
That final point is the crux of the open question. If the protective effect is driven principally by weight loss, it would be expected to accompany any effective weight management intervention. If it persists independently of weight change, it would suggest something about the medication’s action on inflammatory or immune pathways that has yet to be characterised. Distinguishing between those possibilities will require dedicated research.
Building healthcare professionals’ understanding of how medications in this class work – and how to interpret emerging evidence about their wider effects – is the focus of professional training such as the College of Contemporary Health’s GLP-1RAs in Focus, a CPD-accredited online short course.
How routine clinical data complements traditional trials
In Dr Krüger’s view, studies that draw on routine clinical data to compare the effects of medications are an important complement to conventional clinical trials. This is particularly true for GLP-1 agonists such as tirzepatide and semaglutide, sold as Mounjaro, Wegovy and Ozempic.
Because these medications have been on the market for a relatively short time, only a small number of large-scale studies have examined the full range of effects associated with the class. Medical societies and regulatory authorities need more research of this kind to underpin their recommendations.
There is also a practical problem that database research helps to solve. “Clinical trials are increasingly comparing active ingredients with one another,” says Dr Krüger. Regulatory authorities, however, often also require comparisons against the established standard of care rather than against another modern drug – a requirement that raises an ethical difficulty if it means assigning trial participants to older treatment while withholding a therapy that may benefit them.
“Database studies that are benchmarked against the results of traditional clinical trials can fill this gap without actually withholding potentially beneficial therapies such as GLP-1 agonists from study participants,” he says.
What this means for clinical decision-making
By enabling a direct comparison with standard diabetes treatment, Dr Krüger hopes the study will provide an additional tool to support decision-making by patients and their physicians.
For healthcare professionals supporting people who live with both type 2 diabetes and obesity, the practical implication is that the conversation about tirzepatide may extend well beyond glycaemic control and weight. Cardiovascular protection and, potentially, resilience to serious infection now form part of the evidence that can be weighed when treatment options are discussed.
As with all analyses of routinely collected data, the findings describe an association rather than establishing cause and effect, and the mechanisms behind the infection results remain to be confirmed. What the study adds is real-world evidence at a scale, and against a comparator, that trials have not yet delivered.
CCH insight
Findings like these show how quickly the evidence base around GLP-1 medications is expanding, and how much rests on the professionals discussing these treatments understanding both how they work and how to appraise new data with confidence. CCH’s GLP-1RAs in Focus – Why Drugs Like Ozempic Work CPD short course (2 CPD hours, fully online, CPD-accredited) gives healthcare professionals, whether or not they prescribe, a clear grounding in the science behind medications such as tirzepatide, where they fit in treatment pathways, and how to weigh emerging evidence critically.
